Defense World
03 Apr 2026, 07:30 UTC · 24w ago
Verdict
Headline takes no side. We score NVO +0.40 across four claims — moderately bullish.
+0.40moderately bullish
More positive than 60% of ticker scores this week
What the story claims
4 claims · scored −1 bearish … +1 bullish
Novo Nordisk reported Q4 earnings of $1.01 per share and revenue of $12.43 billion, beating consensus estimates of $0.90 and $11.97 billion respectively.
More positive than 76% of claims this week
Morgan Stanley upgraded Novo Nordisk from 'underweight' to 'equal weight' with a $40.00 price target.
Continue reading
5 related stories
Scored by the NIS engine · methodology.
Top 1 mover · tap to explore
More positive than 49% of claims this week
TD Cowen downgraded Novo Nordisk from 'buy' to 'hold' with a $42.00 price target.
So whatA downgrade from a buy rating suggests a reduction in expected growth or valuation headroom.
More negative than 71% of claims this week
Multiple institutional investors, including Banque Pictet and Heirloom Wealth Management, increased their holdings in Novo Nordisk during the fourth quarter.
More positive than 40% of claims this week
Which stocks this story touches
More positive than 60% of ticker scores this week
The company beat EPS and revenue estimates and saw significant increases in institutional holdings, despite mixed analyst ratings.
More negative than 75% of ticker scores this week
Banque Pictet & Cie SA sold 26,340 shares of the company.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
+7.7%
Price agrees with the score
$39.82 vs $36.98 close before publication (Apr 2) · not market-adjusted
NVO chart →